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bstract
Breast cancer is one of the most lethal diseases world-wide. However, there is a large difference in breast cancer incidence among Caucasian,
ispanic, African and Asian (e.g. Chinese) women with Caucasian women being the highest and Asian women being the lowest. It has been
uggested that the dietary factors may account for approximately 50% of the breast cancer. One of such dietary components which are typical to
sian but not Caucasian diet is soy foods. A number of epidemiological studies have suggested that increasing soy consumption could be related
o the decreased risk of occurrence and/or mortality of breast cancer. In this review, we first described briefly different types of soy products
nd their nutritional functions and consumption. Then, we described briefly soybean isoflavones, i.e. genistein (GEN), daidzein, glycitein, and
resented several lines of evidence to demonstrate the possible association of soy flavone food consumption with incidence and prognosis of
reast cancer; finally, we summarized several possible molecular mechanisms, including the effects of GEN as an agonist of ER, epigenetic and
enome-wide effects, activation of peroxisome proliferator-activated receptors, induction of apoptosis and stimulation of autophagy, involved in
he chemo-preventive effects of GEN on breast cancer.
 2013 Beijing Academy of Food Sciences. Production and hosting by Elsevier B.V. All rights reserved.
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.  Introduction
Breast cancer is one of the most lethal diseases in women
n Western countries [1]. While the incidence of breast cancer
n Caucasian women is higher than that in Hispanic and Asian
omen, the incidence of breast cancer has been increasing in
hina [1]. The precise etiological factors for breast cancers are
till not clear. It has been indicated that different dietary fac-
ors partially account for the different incidence of breast cancer
mong Caucasian, Hispanic and Asian women [2,3]. In terms of∗ Corresponding author at: Science Writing Solutions, USA and Fox Chase
ancer Center, Philadelphia, PA 19111, USA. Tel.: +1 443 824 3532.
E-mail addresses: Jinqiang.chen@fccc.edu,
hen jinqiang@yahoo.com (J.-Q. Chen).
eer review under responsibility of Beijing Academy of Food Sciences.
213-4530 © 2013 Beijing Academy of Food Sciences. Production and
osting by Elsevier B.V. All rights reserved.
ttp://dx.doi.org/10.1016/j.fshw.2013.08.002
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ahe dietary factors, there is a large difference in consumption of
oybean products between Asian women and women in Western
ountries. A number of epidemiological studies have suggested
hat increasing soy consumption appears to be related to the
ecreased risk of recurrence and/or mortality. In this review, we
rst described briefly types of soy products and their nutritional
unctions, consumption and production. Then, we presented sev-
ral lines of evidence demonstrating that the association of soy
ood consumption with incidence and prognosis of breast cancer;
nally, we summarized several possible molecular mechanisms
nvolved in the chemo-preventive effects of GEN on breast
ancer.
.  Soybeans,  types  of  soy  food  products  and  their
utritional functions  and  consumption
.1.  Nutritional  value  and  health  beneﬁts  of soybeanSoybean (Glycine  max  (L.) Merr.) (Fig. 1), also called “Shu”
n ancient Chinese, is one of the five main plant foods in China
long with rice, wheat, barley and mille. Soybean is orginated in
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hina and has been cultivated for about 5000 years [4,5]. Soy-
ean was first introduced to Southeast Asia, then to Europe in
8th century [4] and to America in 19th century [6]. Since 1940s,
oybean has become one of the most important economic crops
n America. Currently, United States is the largest soybean pro-
ucer of the world, making up more than 35% of the worldwide
roduction in 2011/2012 season [7]. Soybean has been widely
ultivated in the world with a world-wide annual planting area
f 102.77 million hm2 and a harvest of 239.36 t in the season of
011/2012 [7], generating an economic impact of $114 billion
o farmers around the world.
United States, Brazil, Argentina and China are the current
eaders of soybean production in the world, with a combined
arvest of 205.27 t in the season of 2011/2012, making up 86%
f the worldwide production [7]. In the past 11 years, worldwide
roduction of soybeans has been increasing [8].
The biggest commercial interest in soy is the oil and pro-
ein. Soybean compositions vary depending on variety, location,
limate and farming practices [8]. Dry mature raw soybean typ-
cally contains 8.5% moisture, 36.5% protein, 19.9% lipids, and
.3% dietary fiber, according to USDA nutritional database [9].
rotein and lipid combined make up more than 60% of soybean
n dry weight basis.
Before the recent surge in interests in protein of soybean,
oybean oil was the main purpose of commercial production of
oybean. According to USDA report, soybean oil is the second
argest vegetable oil produced in the world with a total world-
ide production of 42.92 million t, second only to palm oil’s
5.29 million t in the year 2012/2013. Soybean oil contains
5.6% total saturated fatty acids, 22.8% total monounsaturated
atty acids, and 57.7% total polyunsaturated fatty acids [9]. Fat
as been treated as an important issue in human diet for a long
ime and many scientific studies have focused on the impact of
onsuming different types of fat to human health. In the most
ecent release of the Dietary Guidelines for Americans, USDA
xpert panel recommends consuming less than 10% of calories
rom saturated fat and replacing them with monounsaturated
nd/or polyunsaturated fat that is associated with lowering risk
f cardiovascular disease [10]. Soybean oil contains a very high
evel of unsaturated fatty acid and a significant amount of omega-
 fatty acids [11], which is considered as part of the healthy fat
roup. Alpha-linolenic acid (an omega-3 fatty acid) in soybean
il is an essential fatty acid for human nutrition, which means it
annot be synthesized by humans. Regular consumption of foods
ich in omega-3 fatty acids can provide many health benefits,
ncluding reduced cardiac deaths.
t
t
dybean seeds and Tufu.
As more about soybean understood, the focus has shifted
o its other components in the past few decades, especially the
rotein. Protein provides amino acids to human diets. Proteins
rom different sources have different amino acid compositions,
hich will affect its nutritional value to human diets especially
he essential amino acids. There are various methods to evalu-
te nutritional quality of food proteins. The Protein Digestibility
orrected Amino Acid Score (PDCAAS) method is currently the
ost accepted method for such purpose, replacing the Protein
fficiency Ratio (PER) method in 1989. Soy protein’s PDCAAS
core (1.0) is ranked the highest among vegetable proteins, and is
qual to that of milk proteins (casein, whey protein) and egg pro-
ein, indicating that soy protein provides complete amino acids
o human nutrition [12]. In comparison, wheat gluten, another
opular plant protein commonly found in vegetarian diet, only
as a PDCAAS score of 0.25.
Recently, FAO recommended a new method of evaluating
rotein quality – Digestible Indispensable Amino Acid Score
DIAAS), which is said to correct some of the limitations of
DCAAS method [13]. This no doubt will change the way peo-
le evaluate various proteins for their nutritional value. However,
here is not abundance of data available to compare various pro-
eins’ nutritional value using this new method due to the fact
hat this recommendation was just recently released by FAO.
Unlike other proteins, soy protein’s health benefits reach far
eyond just providing amino acids. There have been numerous
tudies on this subject in the past few decades. For instance,
nderson et al. [14] summarized 37 primary studies, and con-
luded that consumption of soy protein rather than animal
rotein significantly decreased serum concentrations of total
holesterol, LDL cholesterol and triglycerides. Its mechanism
as under extensive study. Crouse III et al. [15] established the
irect link of naturally occurring isoflavones in soy proteins and
he lowering of total and LDL cholesterol. However, another
tudy seemed to indicate that isoflavones did not play a key role
n soy protein’s cholesterol lowering effect [16].
On October 26, 1999, based on all the scientific evidences,
DA issued a final ruling on health claim of soy protein peti-
ioned by Protein Technologies International. The ruling states
hat diet low in saturated fat and cholesterol that include 25 g
f soy protein a day may reduce the risk of heart disease.
n the ruling, FAD proposed that the soy food should con-
ain 6.25 g soy protein per serving in order to qualify for
his health claim [17]. This is the most significant event for
he soybean growing and processing industry for the past few
ecades.
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Since FDA’s approval of soy health claim, many studies have
urther demonstrated the link between soy product consump-
ion and lowering the risk of CHD. In 2003, Hermansen et al.
18] reviewed 50 research studies and confirmed the positive
elation between soy consumption and improving cholesterol
rofile. In 2011, Anderson et al. reviewed a total of 43 studies
rom 1996 and 2008 and concluded that consuming a median
f 30 g soy protein per day significantly improve the lipopro-
ein risk factor for CHD. However, soy protein health benefit
s not without controversies. In 2006, American Heart Asso-
iation Science Advisory panel reviewed 22 studies found that
solated soy protein with isoflavones has minimal effect in lower-
ng LDL. Although the finding does not agree with other studies,
he panel still recommends that soy products should be benefi-
ial to cardiovascular and overall health because of their high
ontent of polyunsaturated fats, fiber, vitamins and minerals and
ow content of saturated fat [19].
FDA’s approval of soy health claim serves as fuel for soy
roducts market growth in U.S. market and dramatically changes
he status of soy in mainstream American’s diet. Between 2000
nd 2007, more than 2700 new soy-based food products were
ntroduced in U.S. market, and the soy market grew 4.5 times
o 4.5 billion between 1996 and 2009 [20]. This market grew to
.2 billion in 2011 [21]. According to information presented on
he website of Soy foods Association of North America, energy
ars and soymilk are the two largest categories with soy-based
nergy bars overtaking soymilk’s No. 1 position in 2011. Energy
ars market also represents the largest growth from 2010 to 2011
ith a 14.7% increase in total sales [21].
With extensive conventional news media’s coverage and
nformation flow in the modern media such as Internet, Face-
ook, and Twitter, soy’s healthy image has been established
mong many consumers young and old. United Soybean Board
as been monitoring the consumers’ attitude to soy for many
ears. In 1998, 67% of consumers considered soy products as
ealthy. This percentage increased to over 80% in 2005. It was
lightly down since reaching the peak of 85% in 2007 and 2008
o 81% in 2011 [22] (Fig. 2).With better understanding of soy protein’s health benefit
nd consumers’ increasing acceptance, soy product use has
eached a much wider market. In 2000, USDA approved the
Fig. 2. Survey results of consumers’ attitudes to soy [22].
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se of some soy products in school lunch program [23]. This
et a milestone in soy industry because it was the first time
oy products could be used in USDA school lunch program
s 100% of the serving instead of as an additive. Study in
iddle school of Maryland, USA showed that students accept
oy-based products just as well as other popular school lunch
tems [24] In February of 2012, USDA further approved tofu
nd soy yogurts as a credit for meat/meat alternative component
n school meal planning [25]. This policy became effective on
uly 1, 2012.
The explosion of research on subject of soy and human health
roduced large amount of information, giving a much deeper
nderstanding into soy’s health benefits from molecular level.
any subjects have been extensively studied. Since 1994, the
nternational Symposium on the Role of Soy in Health Pro-
otion and Chronic Disease Prevention and Treatment was
rganized on a mostly bi-annual basis with the 9th symposium
eld in Washington, DC, October 2010. Scientists from around
he world exchanged their scientific findings and knowledge
n various health issues impacted by soy consumption, includ-
ng cholesterol, heart disease, breast cancers, prostate cancers,
one health, menopausal symptom, weight loss, renal function,
nd cognitive function, to name a few [26,27]. Based on all
he findings, soy products can play an important and positive
ole in improving our health if being incorporated into our diet
lthough there are still much to be understood, especially the
echanisms.
.2.  Selected  products  derived  from  soybean
Edamame  – Edamame is immature soybeans sold in fresh or
rozen forms. As a traditional ingredient in Chinese and Japanese
uisine, Edamame can be found in many non-Asian restaurants
n recent years, especially as an ingredient in salad. Frozen
dmame can be easily found in many mainstream grocery
tores.
Soybean sprouts  – Commonly found in Asian cuisine,
specially Chinese, soybean sprouts are the germinating
eeds of soybean under controlled conditions. Compared
o mature soybeans, soybean sprouts contains substantial
mount of good proteins and much higher amount of various
itamins [9].
Soynuts  – In recent years, soynuts has been gaining popular-
ty as a snack in Western world. Soynuts are made from soaked
oybeans that have been fried, baked or roasted. Various flavors
re then applied topically to soynuts to make the finish products.
Soybean  ﬂours  – Soybean flours, or soy flours, are made
rom roasted soybean that have been ground into fine flour. Soy
ours can be found as full fat or defatted versions. It is widely
sed in industry as an ingredient to boost the protein contents of
any food items such as bakery and pasta.
Soybean  oil  – Soybean oil is one of the most important veg-table oil in the world. In 2012/2013, soybean oil makes up 27%
f the world vegetable oil production, second to palm oil (35%)
28]. The recent surge of biofuel industry further expands the
emands of soybean oil [29].
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Soybean  meals  – Soybean meals is the ground soybean cake
rom which soybean oil has been extracted. The high protein
ontent (>40%) makes it an important protein source for feed
ndustry [30,31].
Soymilk  – Soymilk is said to be invented in China by the
egendary An Liu about 2000 years ago [32] with the first written
ecord in AD 82. It is the aqueous extract of soy protein. Soymilk
ontains similar amount of protein and fat as cow’s milk, and it
s free of lactose and cholesterol. Therefore, it is considered as
 healthy beverage and a popular alternative to dairy milk for
opulation that is lactose-intolerant.
Tofu  – Like soymilk, tofu is also invented in China. It is a curd
ade by coagulating soy protein by mineral salts or acid. It is
uch similar to the fresh cottage cheese in Western world which
as made by coagulating cow’s milk. In tofu making, a coagulant
calcium, magnesium salt, or glucono delta-lactone) is used to
recipitate the soy protein from soymilk to form a jello-like curd.
ll tofu products involve the coagulation step. Depending on the
ownstream process, this curd can be converted into different
ypes of products that can be found from today’s supermarket.
he jello-like curd can be further pressed to make tofu with
arious hardness and moisture levels, yielding soft, firm, extra
rm, and super firm tofu. Various flavors can be added to tofu to
reate even more varieties. Historically, tofu is a major source
f protein in the Chinese diet in which meat supply was not
n abundance until recent years. Calcium-coagulated tofu also
erves as an important source of calcium, an essential macro
ineral, which is deficient in typical Chinese diet.
Unfortunately, tofu products vary greatly in their composi-
ions even within the same variety because there is no established
tandard of identity. Different manufacturers choose their own
tandard for the same type of products, resulting in lots of confu-
ion to consumers. Silken, soft, firm and extra firm tofu produced
y several major tofu producers in U.S. contain varying amounts
f proteins [33].
Consumers who are looking for tofu as a protein source will
ace a great challenge of differentiating products from different
rands not only from its appearance, texture, flavor, but also need
o pay attention to its protein content. Standardizing various
arieties of tofu products based on composition will certainly
elp to further promote the products to consumers.
Okara  – Okara is the residual solids from soymilk extraction.
kara typically contains about 80% moisture, 3.2% protein, and
.7% fat on as-is basis [9]. Okara from different manufacturers
an vary greatly depending on the manufacturing techniques.
lthough okara can be found as a cooking ingredient in China,
apan and Korean cuisine, its most popular use is still as feed
aterials for livestock. However, as people understand more
bout human needs for fiber as a nutrient in human nutrition,
nterest in application of okara as food ingredients has been
ncreased in recent years. A simple Google search of “Okara
ecipes” yields over 100,000 listing, indicating the rising inter-
sts in this unique ingredient derived from soybean. In Japan,
kara is used as an ingredient to manufacture extruded okara
nacks.
Natto – Natto is a traditional Japanese soy foods made by
ermenting soybean with strains of Bacillus  subtillis  natto  [33].
t
auman Wellness 2 (2013) 146–161 149
ike some very strong cheeses, Natto’s smell, flavor, and its
limy texture could be challenging for some people to accept.
evertheless, it has become much more popular in recent years
mong U.S. consumers due to its perceived health benefits.
Tempeh – Tempeh is a fermented soybean product originated
n Indonesia. It is made by fermenting dehulled and partially
ooked soybeans with Rhizopus  mold [34]. The extensive net-
ork formed by mycelia binds the soybean together to form a
lock, making it like a fermented soybean loaf. Besides being a
igh protein food, co-fermentation by some bacteria in Indone-
ian Tempeh also produces VB12, an essential vitamin that is
ypically deficient in pure vegetarian diet [35].
Miso – Miso is a popular Japanese food made by fermenting
ice and soybean with a mixture of molds, yeast and bacteria.
raditional miso manufacturing process starts with fermenting
ooked rice with Koji spores (spores from Aspergillus  Oryzae),
ollowed by second fermentation of the fermented rice and
ooked soybean mix by molds, yeasts and bacteria, yielding
 paste material with complex flavor [36]. In U.S., miso is most
ommonly used in miso soup and as seasoning for flavor.
Soy sauce  – Soy sauce is the most common seasoning in
hina and has a recorded history as early as 160 AD [37]. Soy
auce is called Jiang You in China, Shoyu or Tamari Shoyu in
apan, Ketjap or Kecap in Indonesia, Kicap in Malaysian, and
anjang in Korea [37]. Similar to miso, traditional soy sauce
s manufactured by fermenting a mix of wheat and soybean by
arious microorganisms including Aspergillus, lactic acid bacte-
ia and yeasts [38] creating a very complex flavor and aroma
hrough chemical and biochemical reactions during the manu-
acturing and processing steps. Various brands of soy sauce are
ery different in flavor and aroma due to its variations in raw
aterial formulation, starter cultures, and fermentation process.
n recent years, healthy eating trend also promotes the popular-
ty of low salt soy sauce. In modern manufacturing technique,
oy sauce is also made by hydrolysis process, yielding a product
hat is considered by many as inferior.
Soy protein  isolate  – Soy protein isolate is soy protein iso-
ated from soybean ingredient such as soy meals. It contains very
igh level of protein (>90%), and it is nearly carbohydrate and
at-free [39]. Soy protein isolate is widely used in food indus-
ry in protein drink dry mixes, infant formula, soups, liquid
utritional meals, soymilk, frozen desserts, dressings, bakery,
reakfast cereals, pet foods, pasta, cheese alternatives, snack
oods, and protein supplement products.
Texturized meat  alternatives  – As food processing technol-
gy advances, soy protein, either alone or in combination with
ther vegetable proteins, can be processed into various textur-
zed meat substitute products. This type of product, either in
ry, refrigerated or frozen form, is typically similar to and color
atching the corresponding meat. They can be in the form of
lain ingredients or formulated products or in the form of for-
ulated products such as vegetarian meat ball and vegetarian
ausages. This substantially improves the appeals of the productshe vegetarian and healthy eaters.
Cheese and  dairy  alternatives  – Soy cheese is a cheese
nalog made with soy derived ingredients or tofu. These
150 F.-J. He, J.-Q. Chen / Food Science and Human Wellness 2 (2013) 146–161
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sFig. 3. Chemical structures of genistein (G
roducts, such as various varieties of cheese block, slices, and
ream cheese, can be easily found from local health food stores
r the health food section of local grocery stores. Similar to the
airy counterparts, soy cheese comes in various flavors. How-
ver, unlike the dairy versions, the current versions of common
oy cheese and dairy alternatives are not fermented products
40]. It is much similar to the processed cheese or processed
heese foods in dairy market.
Soy yogurt  – Soy yogurt is fermented soy based product
sing soymilk as substrate. Soy yogurt production process is
imilar to traditional yogurt manufacturing in which starter cul-
ures are used to ferment the protein-rich base substrate, yielding
 product that contains healthy soy protein and beneficial pro-
iotics cultures.
Nondairy  desserts  – Soy based ice cream, soy whipped
ream topping, soy-containing frozen desserts and bakery
tems such as soy cheese cake have been in existence for
any years, although its popularity has not yet reached
ainstream.
Nutritional supplements  – Various nutritional or nutraceu-
ical supplement products have been produced from soy bean
rocessing. The most popular ones are Vitamin-E, Lecithin and
soflavone, which can be found in most pharmacies and health
upplement stores in U.S.
.  Soybean  isoﬂavones:  genistein,  daidzein,  glycitein,
nd formononetin
While proteins, soy bean oil and carbohydrates are the
ain components of soy, which are healthy components, soyoods described above also contain varying concentrations of
hytoestrogens (PE) called isoflavones, which are responsible
or many of health benefits including their effects in breast
ells.
s
a
fdaidzein, and glycitein and 17-β estradiol.
.1.  Structures  and  biosynthesis  of  genistein  (GEN),
aidzein, and  glycitein
The phytoestrogens (PE) with estrogen-like structures can be
lassified into four distinct types: isoflavones, coumestans, lig-
ans and prenylflavonoids. Among PEs, isoflavones are present
n high concentrations in soy and soy products [41,42]. The
hemical structures of several isoflavones, genistein, daidzein,
lycitein, and formononetin, are shown in Fig. 3. Isoflavones
re usually present as glycoside conjugates in foods, such as
enistin, diadzin, and glycetin, or their aglycone forms such as
enistein, diadzein, and glycetein. While isoflavones occur in
any types of legumes, soybean contains the highest concen-
ration of isoflavones. Soybean contained a combined amount
f 61.7 mg of diadzein (37.6 mg) and genistern (24.1 mg) per
g of day weight [43]. Diadzin/diadzein, genistin/genestein and
lycetin/glycitein typically account for 40%, 50% and 10%
f total isoflavones, respectively [44]. The relative amounts of
iadzin/diadzein, genistin/genestein and glycetin/glycitein vary
mong different cultivars and geographical locations [45–48].
or example, it has been reported that isoflavone content in
ommercial soybean foods was in the ranges of 1176–3309 g/g
cross years [45] and isoflavone content of soybeans in Asia var-
ed from 699.7–2581.6 g/g with cropping year [46], in Canada
aried from 360–2241 g/g [47] and in Europe (Romania) varied
rom 712 to 1228 mg/g, respectively [48]. Mature soybean seeds
rom Korea and United States contained the highest amounts
f total isoflavone content of (178.81 ±  41.17) mg/100 g and
159.98 ± 43.58) mg/100 g, respectively (Table 1) [49]. The
etailed amounts of diadzin, genistin, and glycetin in a wide
ariety of soybean organs and soy foods (e.g. soy protein con-
entrates soymilk and fermented products such as miso, temph,
ufu and tofu) are listed in Table 1 [49], among which, the mature
oybean seeds contain the highest amounts of diadzin, genistin,
nd glycetin and total amounts of these isoflavones. For soybean
oods, a variety of soybean flours contain the highest amounts
F.-J. He, J.-Q. Chen / Food Science and Human Wellness 2 (2013) 146–161 151
Table 1
Summary of contents of isoflavones in soybean food products.a
NDB # Food description Daidzein Genestein Glycitein Total N CC
99055 Soy cheese, Mozzarella 1.14 ± 0.64 2.60 ± 1.30 2.28 ± 1.06 6.02 ± 2.96 5 B
99056 Soy cheese, Parmesan 1.50 ± 0.00 0.80 ± 0.00 4.10 ± 0.00 6.40 ± 0.0 3 C
99471 Soy cheese, swiss 1.80 4.40 1.70 7.9 1 C
99042 Soy cheese, unspecified 5.79 ± 6.41 11.14 ± 11.31 25.72 ± 20.18 8 B
99043 Soy drink 2.75 ± 1.23 5.10 ± 1.80 7.85 ± 3.04 5 C
09945 Soy fiber 18.80 ± 1.41 21.68 ± 2.89 7.90 ± 0.00 44.43 ± 3.98 6 B
99080 Soy flour (textured) 67.69 ± 19.25 89.42 ± 26.96 20.02 ± 6.77 172.55 ± 50.01 35 B
116117 Soy flour, defatted 64.55 ± 20.20 89.42 ± 26.96 20.02 ± 6.77 172.55 ± 50.01 49
79
27
49
B
16115 Soy flour, full-fat, raw 72.92 ± 10.02 98.77 ± 20.21 16.12 ± .33 178.10 ± 37.06 60 B
16116 Soy flour, full-fat, roasted 89.46 ± 19.72 85.12 ± 21.35 16.40 ± 0.0 165.04 ± 51.03 6 C
16119 Soy meal, defatted 80.77 ± 9.17 114.71 ± 18.42 16.12 ± 1.02 209.58 ± 32.71 8 C
99049 Soy noodle, flat 0.09 ± 0.00 3.70 ± 0.00 3.90 ± 0.00 8.50 ± 0.00 3 C
99038 Soy paste 19.71 ± 5.32 17.79 ± 5.75 6.05 ± 3.01 38.24 ± 11.25 33 B
99060 Soy protein concentrated aqueous
washed
38.25 ± 18.81 52.81 ± 8.35 4.94 ± 0.49 84.65 ± 25.75 11 B
16121 Soy protein concentrate produced
by alcohol extraction
5.78 ± 3.83 5.26 ± 1.78 1.57 ± 0.00 11.49 ± 5.50 21 B
99660 Soy protein drink 27.98 ± 18.19 42.91 ± 25.44 10.76 ± 3.65 81.65 ± 46.04 8 B
16122 Soy protein isolate 30.81 ± 12.73 57.28 ± 14.17 8.54 ± 3.22 91.05 ± 26.00 49 B
99510 Soy yogurt 13.77 ± 12.39 16.59 ± 9.83 2.80 ± 4.12 33.17 ± 26.16 5 B
99072 Soy chips 26.71 ± 0.00 27.45 ± 0.00 54.16 ± 0.00 3 C
99034 Soybean, curd, fermented 12.18 ± 1.91 21.12 ± 1.15 2.30 ± 0.00 34.68 ± 3.89 5 C
99035 Soybeans, flakes, defatted 37.47 ± 24.37 91.22 ± 41.85 14.23 ± 0.00 131.53 ± 64.64 10 C
99036 Soybeans, flakes, full fat 21.75 ± 23.03 39.57 ± 43.82 1.12 ± 0.35 62.31 ± 67.07 9 B
99100 Soybeans, green, mature 61.70 ± 5.84 60.07 ± 12.13 7.07 ± 3.60 128.83 ± 18.66 15 B
99520 Soybeans, mature seeds, canned 26.15 ± 0.64 25.15 ± 12.87 6.1 52.82 ± 16.29 4 B
16109 Soybeans, mature seeds, cooked,
boiled, without salt
30.76 ± 10.64 31.26 ± 8.83 3.75 ± 1.53 65.11 ± 10.57 28 B
16111 Soybeans, mature seeds, dry
roasted (included soy nuts)
62.14 ± 28.04 75.78 ± 25.18 13.33 ± 8.69 148.50 ± 63.12 16 B
16108 Soybean, mature seeds, raw (all
sources)
62.07 ± 20.01 80.99 ± 22.64 14.99 ± 7.45 153.53 ± 43.07 1000 B
99574 Soybeans, mature seeds, raw
(Australia)
39.88 ± 16.98 65.64 ± 19.35 17.12 ± 4.10 120.84 ± 34.12 57 B
99030 Soybeans, mature seeds, raw
(Brazil)
29.09 ± 12.70 67.57 ± 13.69 13.10 ± 3.58 99.82 ± 21.22 58 B
99488 Soybeans, mature seeds, raw
(China)
53.33 ± 13.89 57.98 ± 5.60 11.71 ± 2.35 118.28 ± 21.20 22 B
99575 Soybeans, mature seeds, raw
(Europe)
45.44 ± 10.54 39.78 ± 14.46 22.37 ± 8.19 103.56 ± 18.71 44 B
99092 Soybeans, mature seeds, raw
(Japan)
45.95 ± 22.47 74.33 ± 23.56 9.01 ± 3.21 130.65 ± 41.17 49 B
99093 Soybeans, mature seeds, raw
(Korea)
78.86 ± 19.72 89.32 ± 24.68 18.76 ± 7.13 178.81 ± 47.16 314 C
99040 Soybeans, mature seeds, raw
(Taiwan)
22.77 ± 18.10 45.88 ± 16.78 13.24 ± 5.17 85.68 ± 33.42 22 B
99576 Soybeans, mature seeds, raw
(United States)
61.33 ± 21.48 86.33 ± 20.30 13.33 ± 8.89 159.98 ± 43.58 399 B
16230 Soymilk (all flavors), nonfat, with
added calcium, vitamins A and D
0.30 0.41 0.00 0.70 1 C
99568 Soymilk curd, dried 40.85 ± 1.42 43.45 ± 0.45 83.30 ± 0.89 6 B
99096 Soymilk skin or film (Foojook or
yuba), cooked
17.81 ± 2.98 25.15 ± 5.31 2.69 ± 0.55 44.67 ± 8.12 11 B
99053 Soymilk skin or film (Foojook or
yuba), raw
80.03 ± 21.28 101.40 ± 21.98 15.43 ± 2.99 196.05 ± 46.55 19 B
99014 Soymilk, iced 1.90 ± 0.98 2.81 ± 0.66 4.71 ± 1.64 6 C
99559 Soymilk, made from soy isolate
(purchased in Australia)
2.80 ± 0.00 3.10 ± 0.00 5.90 ± 0.00 3 B
99572 Soymilk, original and vanilla,
fortified or unfortified
4.84 ± 1.71 6.07 ± 0.47 0.93 ± 0.00 10.73 ± 3.99 155 B
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Table 1 (Continued)
NDB # Food description Daidzein Genestein Glycitein Total N CC
99497 Sufu 7.50 ± 2.77 5.46 ± 2.32 0.78 ± 0.46 13.75 ± 4.86 12 C
16114 Tempeh 22.66 ± 8.99 36.15 ± 17.64 3.82 ± 1.45 60.61 ± 27.44 28 B
99081 Tempeh burger 6.40 ± 0.00 19.60 ± 0.00 3.00 ± 0.00 29.00 ± 0.00 3 C
16174 Tempeh, cooked 13.12 21.14 1.39 35.64 2 C
99500 Tempeh, fried 32.90 ± 0.00 39.90 ± 0.00 NA 72.80 ± 0.00 3 B
43476 Tofu yogurt 5.70 ± 0.00 9.40 ± 0.00 1.20 ± 0.00 16.30 ± 0.00 3 C
99084 Tofu, Azumaya, extra firm,
cooked (steamed)
8.0 12.75 1.95 22.70 1 B
99085 Tofu, Azumaya, firm, coked 12.8 16.15 2.40 31.35 2 B
16128 Tofu, dried frozen (Koyadfu) 29.59 ± 2.58 51.04 ± 5.41 3.44 ± 0.00 83.20 ± 9.56 4 C
99529 Tofu, firm, braised 7.28 8.22 1.28 16.79 4 B
99529 Tofu, firm, cooked 10.26 ± 2.48 10.83 ± 3.98 1.35 ± 0.32 22.05 ± 6.36 7 B
16126 Tofu, firm, prepared with calcium
sulfate and magnesium chloride
(nigan)
12.31 ± 4.72 16.10 ± 7.70 2.75 ± 1.28 30.41 ± 13.30 105 B
16129 Tofu, Fried 13.80 ± 2.70 18.43 ± 4.67 2.93 ± 1.13 34.78 ± 7.32 39 B
16162 Tofu, MORI NU, silken, firm 12.42 ± 2.36 16.95 ± 2.49 2.40 29.97 ± 3.75 4 B
16130 Tofu, okara 3.62 ± 2.98 4.47 ± 2.86 1.30 ± 0.38 9.39 ± 6.20 7 B
99097 Tofu, presses (Tua kwa), raw 15.59 ± 2.16 16.01 ± 2.35 2.77 ± 0.85 33.91 ± 5.38 18 B
16427 Tofu, salted and fermented (fuyu) 8.56 ± 3.32 12.99 ± 4.19 1.98 ± 0.59 22.73 ± 7.33 10 B
16132 Tofu, salted and fermented (fuyu) 20.72 ± 9.09 23.83 ± 10.54 4.95 ± 0.04 48.51 ± 21.73 5 C
99495 Tofu, silken 9.15 ± 2.32 8.42 ± 1.50 0.92 ± 0.22 18.04 ± 3.74 25 B
99541 Tofu, smoked 7.50 5.60 NA 13.10 3 B
16127 Tofu, soft, prepared with calcium
sulfate and magnesium chloride
(nigan)
9.49 ± 2.19 11.91 ± 3.82 1.68 ± 0.53 22.61 ± 5.43 18 B
99086 Tofu, soft, Vitasoy-silken 8.59 20.65 NA 29.24 2 C
16147 Veggie burgers or soyburgers,
unprepared
2.36 ± 1.04 5.01 ± 2.91 0.55 ± 0.45 6.39 ± 2.86 31 B
a Adapted and re-arranged from USDA Database for the Isoflavone Content of Selected Foods (U.S. Department of Agriculture:
http://www.ars.usda.gov/SP2UserFiles/Place/12354500/Data/isoflav/Isoflav) [49].
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f diadzin, genistin, and glycetin and total amounts of these
soflavones.
In higher plants, isoflavones are biosynthesized via a branch
f the general phenylpropanoid pathway, which begins from
he amino acid phenylalanine naringenin, an intermediate of
he pathway, is sequentially converted into the isoflavone
enistein by isoflavone synthase and a dehydratase. Similarly,
aringenin chalcone, another intermediate is converted to the
soflavone daidzein by sequential action of chalcone reductase,
ype II chalcone isomerase, and isoflavone synthase. Soybean
ses isoflavones to stimulate soil-microbe rhizobium to form
itrogen-fixing root nodules [50].
.2.  Metabolism  of  isoﬂavones  by  intestine  bacteria  and
ifference in  the  metabolism  rate  of  isoﬂavones  between
.S. Caucasian  population  and  Asian  population
When taken in human intestine, soy isoflavones undergo
xtensive transformations during passage through human diges-
ive tract, especially in the colon, where members of the
omplex commensal microbiota are capable of carrying out
ynergistically a broad range of metabolic transformations
hat affect the fate and the biological activity of phytochemi-
als. Diverse bacterial species present in the colon hydrolyze
he glucose conjugated forms of isoflavones, releasing the
w
a
Lble portion for mean. N = number of samples analyzed; CC = confidence code;
orresponding aglycones, which may undergo further micro-
ial conversions (especially reductions) giving rise to a wide
pectrum of isoflavone-derived compounds.
Equol, one of the bio-transformed metabolites of isoflavones,
s a more potent estrogenic metabolite, and possesses a greater
ffinity for estrogen receptors (ERs), unique antiandrogenic
roperties, and superior antioxidant activity [51]. Equol has
n activity of approximately 0.2%–0.5% of estradiol [52,53].
lthough this affinity is relatively low, equol is still capable of
ignificantly competing with estradiol for ERs because of its
arge amount produced from soy products.
The end-products of microbial transformations are subjected
o substantial individual variations, reflecting the impact of the
olonic microbiota, since intestinal bacteria may greatly increase
r compromise the biological activity of dietary isoflavones.
he clinical effectiveness of soy isoflavones may be related to
bility to biotransform soy isoflavones to equol [54]. There are
arge differences in the metabolism rates of GEN and daidzein
etween U.S. Caucasian population and Asian population. Only
pproximately 30%–50% of the general population is able to
etabolize daidzein to equol. Only 25%–35% of the U.S. Cau-
asian population is capable of converting daidzein to equol
hereas 40%–60% of Asian people in high soy consumption
reas is capable of converting daidzein to equol. Hispanic or
atino women are also more likely to be equol producers.
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pproximately 80%–90% of people harbor the bacteria required
o produce O-desmethylangolensin (ODMA). The frequency of
quol producers of vegetarians was found to be approximately
0%, similar to the reported frequency in Japanese adults con-
uming soy, and much higher than those for non-vegetarian
dults (25%). One Japanese study found that consumption of
airy products was significantly higher in those who did not
xcrete equol than in those who did. It has been found that sea-
eed consumption can enhance intestinal production of equol.
hese observations could partially explain some of the breast
ancer protective effects of Asian diets high in both seaweed
nd soy. Another U.S. study comparing Korean American and
aucasian American women found that the prevalence of equol-
roducers was higher (51% vs. 36%) whereas the prevalence
f ODMA-producers was lower (84% vs. 92%) in the Korean
mericans as compared to those of Caucasian American women
55].
The differences in equol production rate could partially
xplain the generally tepid effects found for soy consumption
n studies of European and U.S. populations compared to Asian
opulations (see below). This high variability in equol produc-
ion is presumably due to inter-individual differences in the
omposition of the intestinal microflora, which may play an
mportant role in the mechanisms of action of isoflavones. It
s possible that Chinese populations could have a genetic pro-
le different from other populations that are relatively new to
oy consumption because Chinese populations already have had
ore than 5000 years to develop their ability to digest and extract
utrients from soybeans.
.  The  association  of  soy  isoﬂavone  food  consumption
ith incidence  and  prognosis  of  breast  cancer
.1.  Differences  in  breast  cancer  incidence  between  Asian
omen and  women  from  Western  developed  countries  in
urope
Breast cancer is one of the most lethal diseases in women with
pproximately 1.4 million women diagnosed with breast can-
er and approximately 459,000 deaths in 2008 world-wide [56].
here are large differences in breast cancer incidence between
sian women and women in U.S. and the developed countries in
urope. For women in the U.S. and European countries, breast
ancer death rates are higher than those for any other cancers,
nly second to lung cancer [56].
Compared to that in U.S. and European countries, breast can-
er incidence in China and other Asian countries are much lower
ith the risk for an Asian woman having been recorded as nearly
even times lower in breast cancer risk than that for an American
oman [57]. While breast cancer rates among Asian-Americans
re lower than those of U.S. whites, cancer rates among Asian-
mericans are considerably higher than those prevailing in
omen in Asian countries, suggesting that the increased riskactors are not only related to genetic factors but also related to
nvironmental and dietary factors [58]. There are differences in
reast cancer pathology and incidence rates across racial groups.
mong women younger than 50 years, African Americans are
t
c
t
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ot only at a greater risk for developing breast cancer but may
lso be more likely to present with more aggressive, steroid
eceptor negative, and higher-grade tumors [59–61].
Breast cancer is also the most common cancer diagnosed
mong Chinese women. A recent study has revealed that the
rude incidence and cancer mortality of breast cancer in Chinese
omen are 47.64/100,000 and 10.41/100,000, respectively, and
he cumulative incidence rate for women with ages ranging from
 to 74 years is 3.44%, and that both crude and adjusted incidence
ates for women in urban areas were much higher than those in
ural areas [62]. A modeling analysis on the effects of repro-
uctive and demographic changes on breast cancer incidence in
hina predicted that breast cancer incidence in China will be
ncreased substantially from current rates, estimated at 10–60
ases/100,000 women, to more than 100 new cases/100,000
omen who aged 55–69 years by 2021, i.e. there will be 2.5 mil-
ion cases of breast cancer by 2021 among the 130 million Chi-
ese women aged 35–49 years old in 2001 and that some changes
n lifestyle that might reduce an impending epidemic of breast
ancer by 27,000 cases [62,63,1]. The gradually increasing trend
n breast cancer rates has also seen in other eastern Asian regions
e.g. Japan, Korea and Taiwan (China)) and southeastern Asian
egions (e.g. Philippines, Singapore and Thailand) [64]. Increas-
ng trends in developing counties are often considered as the
esult of the “westernization” of life styles [56], dietary habits
nd exposure to exogenous estrogen, toward a distribution closer
n profile to that of women in industrialized countries.
The differences in genetics, endogenous hormone levels
nd hormone metabolism, growth patterns, diets and other
nvironmental factors among Asian, U.S. Caucasian and
frican-American and Latino women may alter some of these
elative risks quantitatively. Then, the key question is what are
he key factors contributing to this discrepancy?
One of such factors could be the difference in endogenous
evels of estrogens between Asian and Caucasian and African-
merican women. The racial differences in premenopausal
ndogenous hormones between African-American, Caucasian
nd Asian-American women were reported. For example,
oldin et al. [65] compared the plasma estrogen levels of
remenopausal Caucasian woman living in Boston with those
f Asian women recently immigrants from Southeast Asia to
awaii and found that Caucasians had 30%–75% higher plasma
strone and estradiol levels than their age-matched cohorts in
awaii, and that Caucasians had 3-fold higher plasma levels of
stradiol. Pinheiro et al. [66] assayed estradiol, progesterone,
rolactin, sex hormone binding globulin (SHBG), insulin-like
rowth factor-I (IGF-I), and IGFBP-3 in 111 African American
nd 111 Asian American women, matched to 111 Caucasian
omen on age, day of luteal phase, and day, time, and fasting
tatus at blood collection to determine the association between
ace and hormone levels using robust linear regression methods.
heir analysis revealed that African Americans had 18% higher
evels of estradiol, 17% higher free estradiol. Compared with
hat of Caucasian women, Asian Americans had 22% higher
alculated free estradiol. The hormone differences were found
o be consistent with breast cancer risk between Caucasians
nd African Americans but were inconsistent with breast cancer
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isk between Asian Americans and Caucasians [66]. It has been
nown that prolonged exposure to excess estrogens could be an
mportant risk factor for the development of breast cancer [67].
hus, the difference in endogenous levels of estrogens among
sian-, Caucasian- and African-women may partially explain
he differences in breast cancer incidence among different racial
omen.
Another important factor that may account for the discrep-
ncy in breast cancer incidence among different racial women
ould be the differences in their daily dietaries. There are dif-
erences in dietaries particularly in consumption of soybean
roducts between women in Western countries and women in
sian countries. Approximately 50% of all newly diagnosed
reast cancers could be attributed to diets. Thus, identification of
he dietary factors differentially consumed among populations
ith increased breast cancer risk (e.g. Caucasians) compared
o those with low risk (e.g. Asians) would offer new etiologic
nsights and opportunities for prevention and reduction of breast
ancers. One such dietary component which is typical to the
sian but not the Caucasian diet is the consumption of soy foods.
This is evident by the fact that the breast cancer incidence
or Asian women who immigrated to U.S. was higher than that
f women in Asian countries. It is presumed that migration to
he U.S. brings about a change in endocrine function among
sian women and that the high intake of soy foods in Asia and
ts reduced intake among Asian-Americans partly explain the
ncrease of breast cancer rates in Asian-Americans. For exam-
le, Wu et al. [58] conducted a population-based case–control
tudy of breast cancer among Chinese-, Japanese-, and Filipino-
merican women in Los Angeles County, MSA, San Francisco
nd Oakland in California and Oahu in Hawaii. They found that
ntake of a soybean product, tofu, was more than two times as
igh among Asian-American women born in Asia compared to
hose born in the U.S. Among migrants, intake of tofu decreased
ith years of residence in the U.S. Breast cancer risk decreased
ith increasing frequency of intake of tofu after adjustment for
ge, study area, ethnicity, and migration history; the adjusted
R associated with each additional serving per week was 0.85
95% CI = 0.74–0.99). The protective effect of high tofu intake
as observed in pre- and post-menopausal women. The ques-
ion is whether soy, and more specifically soy isoflavones (e.g.
EN), is a dietary component that may help to explain the dra-
atic disparity in breast cancer risk among these populations
58].
.2.  The  association  of  isoﬂavone-containing  soy  food
onsumption with  breast  cancer  prognosis
A number of studies have been conducted to investigate the
ssociation between the soy food consumption and breast cancer
ncidence/prognosis (see summary in Table 2). Qin et al. [68]
erformed a meta-analysis on 21 independent studies including
4 case–control studies and 7 cohort studies from 1966 to 2006
nd examined the association between soy food consumption
i.e. isoflavone intake) and breast cancer risk. They used the
andom-effects model to estimate the pooled relative risk (RR).
he pooled RR of breast cancer for soy food intake was 0.75
w
t
a
iuman Wellness 2 (2013) 146–161
ith a 95% CI of 0.59–0.95. This study showed that tofu and
iso, two main types of soy foods in Japan and China, had
lear protective effects and that isoflavone intake resulted in
 20% decrease in breast cancer risk. Additionally, when the
tudies published in both Japanese and Chinese were taken into
ccount, an inverse association between soyfood tofu and breast
ancer risk was relatively stronger. This meta-analysis supported
he hypothesis that soy food intake could be associated with a
ecreased breast cancer risk due to the isoflavones.
A number of subsequent epidemiological studies have been
onducted with more comprehensive information about the soy
ood, and more accurate assessment of the isoflavones. For
xample, Guha et al. [69] examined the role of soy isoflavone
ntake and the incidence of breast cancer risk by estrogen
eceptor (ER) status, menopausal status, and tamoxifen (TAM)
herapy. A cohort of 1954 women breast cancer survivors,
iagnosed during 1997–2000, was prospectively followed for
.31 years and 282 breast cancer recurrences were ascertained.
his study revealed: 1) a trend for a reduced risk of cancer
ecurrence with increasing quintiles of daidzein and glycetin
ntake compared to no intake among postmenopausal women;
) among postmenopausal women treated with TAM, there was
n approximately 60% reduction in breast cancer recurrence as
ompared to the highest to the lowest daidzein intakes and 3)
oy isoflavones consumed at levels comparable to those in Asian
opulations may reduce the risk of cancer recurrence in women
eceiving TAM therapy and moreover, appears not to interfere
ith TAM efficacy.
Several epidemiological studies [70–76] evaluated the asso-
iation between soy food intake and breast cancer risk of women
n different regions in mainland China. For example, Shu et al.
70] investigated a cohort with 5033 women aged from 20 to 75
ears old who were diagnosed between 2002 and 2006 recruited
nd followed up through 2009. This study revealed: 1) soy food
ntake was inversely associated with mortality and recurrence
nd 2) this trend was independent of ER status or TAM usage.
hose in the highest quartile of soy protein intake not taking
AM had less recurrence than TAM users consuming the least
mount of soy. In another study, Kang et al. [71] recruited 524
atients in northwest region in China who underwent surgery for
reast cancer between August 2002 and July 2003 and received
djuvant endocrine therapy. Their results indicated that high
ietary intake of soy isoflavones was associated with lower risk
f recurrence among post-menopausal patients with breast can-
er positive for ER and progesterone receptor (PR) and those
ho were receiving anastrozole as endocrine therapy. Zhang
t al. [72] consecutively recruited 438 patients with primary
reast cancer and compared them with 438 health women in
uangdong province (South China) from June 2007 to August
008. They observed a statistically significant inverse associ-
tion of soy isoflavone intake with breast cancer risk, which
as more evident among premenopausal women. In consistent
ith this observation, a case–control study by Zhu et al. [73]
ith a total of 183 patients with breast cancer and 192 con-
rols recruited from 2008 to 2011 in south China also indicated
n association of the highest relative to lowest soy isoflavone
ntake with a 58% decrease risk of breast cancer. Higher
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Table 2
The association of isoflavone-containing soy food consumption with breast cancer recurrence/prognosis.
Authors/reference Year Type of study/number of patients
Country/regions
Major findings/conclusions Statistical parameters/outcomes
Qin et al. [68] 2006 Mega-analysis (14 case–control
studies and 7 cohort studies)
International
A 20% reduction in breast cancer
risk. Soyfood intake may be
associated with decreased risk of
breast cancer
RR = 0.81; 95% CI: 0.67–0.99
Guha et al. [69] 2009 Prospective study Cohort/1954 Soy isoflavones consumed at levels
comparable to those in Asian
populations may reduce the risk of
cancer recurrence in women
receiving tamoxifen therapy and not
to interfere with tamoxifen efficacy
HR: 0.48; 95% CI: 0.21–0.79,
p = 0.008
Shu et al. [70] 2009 Population-based cohort study/5042
female breast cancer survivors in
Shanghai/China
Soy food intake, as measured by
either soy protein or soy isoflavone
intake, was inversely associated with
mortality and recurrence
HR: 0.71; 95% CI: 0.54–0.94 for
total mortality
95% CI: 0.54–0.87 for recurrence
Kang et al. [71] 2010 Follow up study with 524 patients
underwent surgery for breast cancer
in Northeast China
High dietary intake of soy
isoflavones was associated with
lower risk of recurrence among
post-menopausal patients with breast
cancer positive for ER and PR and
those who were receiving anastrozole
as endocrine therapy
HR: 1.05, 95% CI: 0.78–1.71; p for
trend: 0.87 for overall death rate
HR = 0.67, 95% CI 0.54–0.85, p for
trend = 0.02 for recurrence
Zhang et al. [72] 2010 A hospital-based case–control
study/438 Chinese women with
breast cancer residing in Guangdong
province (South China)
A statistically significant inverse
association between soy isoflavone
and soy protein intake with breast
cancer risk
95% CI: 0.54 (0.34–0.84) for soy
isoflavone
95% CI: 0.62 (0.40–0.96) for soy
protein
Zhu et al. [73] 2011 A case–control study/183 women
with breast cancer in South China
The highest relative to lowest soy
isoflavone intake was associated with
a 58% decrease risk of breast cancer;
a high intake of soy food was
inversely associated with breast
cancer risk, the effect depending to
some extent on the hormone receptor
status (ER+/PR+)
OR = 0.57, 95% CI: 0.29–0.83
OR: 0.50, 95% CI: 0.38–0.95 for
highest intake of soy isoflavone and
soy protein
Kang et al. [74] 2012 A prospective study with 256
patients with breast cancer in Inner
Mongolia (North China)
Soy intake is associated with a
significant reduced death risk of
breast cancer in Chinese population
OR: 0.25, 95% CI: 0.09–0.54 for
highest soy isoflavone
OR: 0.38, 95% CI: 0.17–0.86 for the
higher consumption of soy protein
Zhang et al. [75] 2012 A prospective study with breast
cancer patients in Inner Mongolia
(North China)
An average intake of soy isoflavone
above 17.3 mg/day reduced the
mortality of breast cancer by about
38%–36%
HR: 0.71; 95% CI: (0.52–0.98) for
high soy protein intake
HR: 0.59, 95% CI: 0.40–0.93 for
high intake of soy isoflavone
Dong et al. [76] 2011 A meta-analysis of prospective
studies/International Populations
Soy isoflavones intake is associated
with a significant reduced risk of
breast cancer incidence in Asian
populations, but not in Western
populations
RR: 0.89, 95% CI: 0.79–0.99 for
isoflavone consumption
RR: 0.76, 95% CI: 0.65–0.86 for
Asian populations
RR: 0.97, 95% CI: 0.87–1.06 for
Western populations
Nechuta et al. [77] 2012 A prospective study with 5514 breast
cancer survivors with a diagnosis of
invasive breast cancer from 2 US
cohorts and 1 Chinese cohort.
Consumption of ≥10 mg
isoflavones/day was associated with a
nonsignificant reduced risk of
all-cause and breast cancer-specific
and a statistically significant reduced
risk of recurrence
Postdiagnosis soy food consumption
of ≥10 mg isoflavones/day was
associated with a nonsignificant
reduced risk of breast cancer-specific
mortality and a statistically
significant reduced risk of recurrence
HR: 0.87; 95% CI: 0.70, 1.10 for low
consumption of ≥10 mg isoflavones
HR: 0.83; 95% CI: 0.64, 1.07 for
breast cancer specific
HR: 0.75; 95% CI: 0.61, 0.92 for
recurrence of breast cancer
Hin b
R: hazard ratios; 95% CI: 95% confidence interval; RR: relative risk.oth U.S. and Chinese women
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exposure to soy isoflavonoids, equol in particular, may facili-
tate clearance and catabolism of endogenous estrogen to more
benign 2-hydroxylated metabolites.
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onsumption of soy protein also decreased breast cancer risk by
4 as compared with the lowest intake. The inverse association
etween highest intake of soy isoflavone/soy protein with the
reast cancer risk was statistically significant in postmenopausal
omen. In the ER/PR status stratified analysis, a significantly
educed risk was observed for ER+/PR+ breast cancer among
ighest intake of soy isoflavone and soy protein. Two other stud-
es [74,75] also showed that the soy food intake is associated
ith longer survival and low recurrence among breast cancer
atients. Dong et al. [76] conducted another meta-analysis of 18
rospective studies including 4 studies of breast cancer recur-
ence and 14 studies of breast cancer incidence through 2010.
his analysis revealed that soy isoflavones consumption was
nversely associated with risk of breast cancer incidence. How-
ver, the protective effect of soy was only observed among
tudies conducted in Asian populations but not in Western popu-
ations. Soy isoflavones intake was also inversely associated with
isk of breast cancer recurrence. This study suggests that soy
soflavones intake is associated with a significant reduced risk
f breast cancer incidence in Asian populations, but not in West-
rn populations. Nechuta et al. [77] prospectively evaluated the
ssociation between post-diagnosis soy food consumption and
reast cancer outcomes among U.S. and Chinese women using
ata from the After Breast Cancer Pooling Project. The analysis
ncluded 9514 breast cancer survivors with confirmed invasive
reast cancer between 1991 and 2006 from 2 U.S. cohorts and 1
hinese cohort. This study revealed that isoflavone consumption
as inversely associated with recurrence among both U.S. and
hinese women, regardless of whether data were analyzed sep-
rately by country or combined. This large study of combined
ata on U.S. and Chinese women revealed that post-diagnosis
oy food consumption of ≥10 mg isoflavones per day was associ-
ted with a non-significant reduced risk of breast cancer-specific
ortality and a statistically significant reduction in risk of recur-
ence. Another meta-analysis of epidemiological studies of soy
onsumption and breast cancer risk among European women
lso have indicated that soy foods consumed at levels com-
arable to those in Asian populations have, in some cases, a
ignificant reduction in breast cancer risk and that women who
re at increased risk of breast cancer due to polymorphisms in
enes associated with the disease may especially benefit from
igh soy isoflavone intake [78]. Altogether, the above described
pidemic studies have suggested that the intake of soy products
ay protect against the occurrence of breast cancer because of
he considerable amount of isoflavones they contain.
.  Possible  molecular  mechanisms  of  chemopreventive
ffects of  genistein  on  breast  cancer
Soy isoflavones are structurally similar to endogenous estro-
ens (Fig. 4) and may affect breast cancer through both
ormonally mediated and non-hormonally related mechanisms.
mong soy isoflavones, genistein (GEN) is believed to be a
otent chemopreventive agent for breast cancer and thus, more
tudies have been focused on its chemopreventive effects on
reast cancer cells. Recent studies have suggested that GEN
an enhance the anticancer capacity of an estrogen antagonist,
F
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AM, especially in ER-positive breast cancer cells. The
hemopreventive effects of GEN could be mediated via the
everal pathways and mechanisms.
.1.  GEN  as  an  agonist  of  ERβ  and  its  effects  on
ndogenous  estrogen  metabolism
Endogenous estrogens (e.g. 17β-estradiol, E2) synthesized in
he body have significant impact on gene regulation by activating
Rs in diverse cell types. While E2 plays very important roles
n the growth and development of breast, prolonged exposure to
xcess E2 and/or exogenous estrogen-like chemicals has been
nown to be the key risk factor for the development of breast
ancer. Due to its structure similarity to E2, GEN possesses estro-
enic properties and can compete with E2 for binding to ERs.
ffinity of GEN is much higher toward ER  than toward ER
79]. GEN can serve as either an agonist or antagonist for ERs,
epending on exogenous E2 levels. At higher exogenous E2,
EN may act as the ER antagonist whereas at lower exogenous
2, it may act as agonist.
Several in  vitro  and in  vivo  studies [80–82] have shown that
EN is capable of stimulating growth of some ER-containing
reast cancer cells. It has been found that GEN is able to increase
roliferation of estrogen-dependent breast cancer cells when
t is not co-treated with an estrogen antagonist. For example,
u et al. [80] suggested that consumption of products contain-
ng GEN might not be safe for postmenopausal women with
strogen-dependent breast cancer. These effects of GEN could
e completely abolished by co-treatment of MCF-7 cells with
ither ICI 182780 or TAM, the estrogen antagonists. GE has
een found to decrease efficiency of TAM and letrozole, drugs
ommonly used for breast cancer therapy [83,84] and to inhibit
mmune response toward cancer cells [85].
In addition to their effects on ERs, soy isoflavonoid have been
hown to cause effects on endogenous estrogen metabolism.
ood et al. [86] evaluated the effects of dietary soy isoflavonoids
n endogenous estrogen metabolism in a postmenopausal pri-
ate model. The results of this study suggest that long-termig. 4. Possible molecular mechanisms of chemopreventive effects of genistein
n breast cancer.
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As mentioned above, GEN displays weak estrogenic activity
ediated by ERs with a preferential binding to ER. Several iso-
orms of ER, namely ER1, ER2, ER3, ER4 and ER5,
re generated by alternative splicing [87,88]. Cappelletti et al.
89] investigated the interaction between GEN and the vari-
us isoforms of ER  in two human breast cancer cell lines,
47D and BT20. They evaluated the effect of GEN individu-
lly and in combination with E2 on mRNA expression of ER
soforms evaluated by a triple primer RT-PCR assay. In T47D
ells, E2 caused a 6-fold increase in total ER  and modified
he relative expression pattern of the various isoforms, i.e. up-
egulating the ER2 but down-regulating the ER5 isoform.
EN up-regulated ER2 and ER1 in T47D cells, and after
EN treatment, the ER2 isoform became prevalent. While
n BT20 cells it almost doubled the percent contribution of
R1 and ER2 to total ER. GEN, through the modulation
f ER  isoform RNA expression, inhibited estrogen-promoted
ell growth, without interfering with estrogen-regulated tran-
cription. ER  and its isoforms may be involved in a self-limiting
echanism of estrogenic stimulation promoted either by the nat-
ral hormone or by weaker estrogen agonists like GEN. Thus, by
egulating the functions of ER, GEN confers protective effects
n breast cancer cells.
.2.  Epigenetic  and  genome-wide  effects  of  GEN
Epigenetics refers to functionally relevant modifications to
he genome that do not involve a change in the nucleotide
equence of the gene. Epigenetic modifications include DNA
ethylation and histone modification. Gene expression can be
ontrolled through the action of repressor proteins that bind
ilencer regions of the DNA. These changes may remain through
ell divisions for the remainder of the cell’s life and may also
ast for multiple generations. However, there is no change in
he underlying DNA sequence of the organism, instead, non-
enetic factors cause the organism’s genes to express themselves
ifferently [90,91].
An important mechanism by which GEN inhibits breast
ancer is related to its potential impacts on epigenetic pro-
esses [92]. In fact, several recent studies have reported that
EN confers the epigenetic effects. For instance, Li et al. [92]
nvestigated the impacts of GEN on epigenetic regulation dur-
ng breast tumorigenesis. They examined the effects of GEN
n epigenetic alterations of two key tumor suppressor genes,
21(WAF1)(p21) and p16(INK4a)(p16), and two tumor promot-
ng genes, BMI1 and c-MYC, in an breast cancer transformation
ystem. Their results have shown: 1) GEN significantly inhibited
rowth of precancerous breast cells and breast cancer cells dose-
ependently but caused little effect on normal human mammary
pithelial cells; 2) GEN up-regulated expression of p21 and p16
hereas down-regulated expression of BMI1 and c-MYC; 3)
EN treatment altered histone modifications in the promoters
f p21 and p16 and the binding ability of the c-MYC-BMI1
omplexes to p16 promoter, contributing to GEN-induced epi-
enetic activation of these genes; and 4) an orally-fed GEN
iet prevented breast tumorigenesis and inhibited breast can-
er development in breast cancer mice xenografts. These results
t
a
m
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uggest that GEN may repress early breast tumorigenesis by
pigenetic regulation of p21 and p16 through impacting histone
odifications and the BMI1-c-MYC complex recruitment to the
egulatory region in their promoter regions.
Another study revealed that the epigenetic reactivation of
R by GEN enhanced hormonal therapy sensitivity in ER-
egative breast cancer. It has been known that DNA methylation
f the promoter region of ER  is an epigenetic mechanism
y which the abundance of ER  mRNA is regulated and a
ifferentially methylated single CpG-site is involved in ER
ranscription [93]. Inactivation of ER  due to the methylation
f the promoter region B of ER  occurs in part of breast cancer
ells, i.e. ER-negative breast cancer cells [94]. Another study
95] revealed that the degree of ER  gene promoter methyla-
ion correlated with ER  expression and epigenetic alteration
f ER  gene may play an important role in the pathogenesis of
amilial breast cancer patients among Chinese women. Li et al.
96] investigated the in  vitro  and in  vivo  epigenetic effects of
EN on ER  reactivation and found that GEN reactivated ER
xpression in ER-negative MDA-MB-231 breast cancer cells
nd that this effect was synergistically enhanced when GEN was
ombined with, a histone deacetylase (HDAC) inhibitor and tri-
hostatin A. GEN treatment also re-sensitized ER-dependent
ellular responses to E2 and TAM. Further studies revealed
hat GEN can lead to remodeling of the chromatin structure in
R promoter, contributing to ER  reactivation. Consistently,
E significantly prevented cancer development and reduced the
rowth of ER-negative mouse breast tumors. Dietary GEN fur-
her enhanced TAM-induced anti-cancer efficacy due, at least
n part, to epigenetic reactivation of ER. The results reveal
 novel therapeutic combination approach using bioactive soy-
ean products, e.g. GEN and anti-hormone therapy in refractory
R-negative breast cancer, which will provide more effective
ptions in breast cancer therapy.
GEN also has an impact on gene expression at a genome-wide
cale. Gertz et al. [97] performed chromatin immunoprecipitat-
on experiments followed by sequencing (ChIP-seq) to identify
R binding sites, and RNA-sequence in endometrial can-
er cells treated with GEN or E2. GEN induced thousands of
R binding sites and expression changes of more than 50
enes, representing a subset of E2-induced genes. Genes affected
y E2 were highly enriched for ribosome-associated proteins
hereas GEN failed to regulate most ribosome-associated
roteins and instead enriched for transporters of carboxylic
cids. Treatment-dependent changes in gene expression were
ssociated with treatment-dependent ER  binding sites. GEN
xhibited a similar relationship to E2 in the breast cancer line
-47D, where cell type specificity played a much larger role
han treatment specificity. Overall, GEN clearly regulates gene
xpression through ER  on a genome-wide scale, although
ith lower potency resulting in less ER  binding sites and
ess gene expression changes compared to those induced by
2. Zhang et al. [98] treated five-week-old mouse mammaryumor virus-erbB2 female transgenic mice with low-, normal-
nd high-levels of estrogen and then gave each group of ani-
als with soybean feed or with control feed. Their results
uggest that dietary soy isoflavones promote breast cancer at low
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strogen levels but inhibit breast cancer at high estrogen levels.
his effect may only occur during the initiation stage of breast
ancer.
.3.  Effects  of  GEN  on  activation  of  peroxisome
roliferator-activated  receptors  (PPARs)
Peroxisome proliferator-activated receptors (PPARs), a
roup of transcription factors, are involved in regulation of
 large number of genes [99] and play essential roles in the
egulation of cellular differentiation, development, and carbo-
ydrate, lipid, and protein metabolisms, and tumorigenesis of
igher organisms [100–102]. Three forms of PPARs, namely
PAR, PPAR/  and PPAR, which are transcribed from
ifferent genes, are known. GEN is capable of binding and acti-
ating all three PPAR isoforms, , , and . GEN can directly
nteract with the ligand binding domain of the PPAR  with a
i being 5.7 mmol/L [103]. At concentrations ranging from 1
o 100 mol/L, GEN activated PPARs in breast cancer MCF-7
ells, T47D cells and MDA-MD-231 cells in a dose-dependent
anner. Several studies have shown that both ERs and PPARs
nfluenced each other and therefore induce differential effects
n a dose-dependent manner and the final biological effects of
EN are determined by the balance among these pleiotrophic
ctions [104,105].
.4.  Effects  of  GEN  in  induction  of  apoptosis
Apoptosis is the process of programmed cell death (PCD)
haracterized by blebbing, cell shrinkage, nuclear frag-
entation, chromatin condensation, and chromosomal DNA
ragmentation [106]. It has been known that GEN can stimulate
ell growth activity at nanomolar concentrations but inhibits cell
rowth at micromolar concentrations. GEN inhibits cell prolif-
ration and triggers apoptosis in human breast cancer cells and
riple negative breast cancer cells (TNBC), which lack ER, PR
nd overexpression of human epidermal growth factor receptor
 (HER2). Shim et al. [107] observed that treatment of MCF-
 cells with GEN at 100 m/L effectively induced apoptosis
ia activation of calpain, caspase 7 and poly (ADP ribose) poly-
erase and increased phosphorylation of p38 mitogen-activated
rotein kinase, and increased phosphorylation of apoptosis
ignaling kinase 1. It has been known that GEN in combina-
ion with photoactivated hypericin suppressed the expression of
cl-2 and Akt in human breast cancer cells [108].
It is worth noting that GEN causes inhibitory effects on MDA-
B-231 cells, a typical TNBC [109,110]. NF-B signaling
athway is involved in regulation of a number of important
iological processes including proliferation, differentiation, and
poptosis by regulating the transcription of target genes and is a
ommonly active pathway in TNBC [111]. Treatment of these
ells with GEN caused a dose-dependent decrease in NF-B/p65
rotein levels and DNA-binding activity of NF-B, down-
egulation of Bcl-2, a pro-apoptotic protein and up-regulation
f Bax, an apoptotic protein. Because the promoter of Bcl-2
ontains NF-B binding sites, GEN might inhibit the expres-
ion of Bcl-2 via down-regulation of NF-B. Treatment of
s
a
i
suman Wellness 2 (2013) 146–161
DA-MB-231 cells with GEN resulted in cleavage of caspase-3
nd induction of caspase-3 activity in a dose-dependent manner.
EN inhibited NF-B activity via the MEK5/ERK5 pathway
nd cell growth, and induced apoptosis, indicating that inhibi-
ion of the MEK5/ERK5/NF-B pathway may be an important
echanism by which GEN suppresses cell growth and induces
poptosis in TNBC. Pan et al. [110] observed that treatment of
DA-MB-231 cells with GEN resulted in G2/M phase accumu-
ation of cells. These results suggest that inhibition of NF-B
ctivity via the Notch-1 pathway may be a mechanism by which
EN suppresses the growth of TNBC.
.5.  Role  of  GEN  in  stimulation  of  autophagy
Autophagy is the basic catabolic mechanism involved in
ell degradation of unnecessary or dysfunctional cellular com-
onents through the lysosomal machinery. The breakdown
f cellular components can ensure cellular survival during
nfavorable conditions such as starvation by maintaining cel-
ular nutritional and energy levels [112]. Proper regulation of
utophagy ensures the synthesis, degradation and recycling of
ellular components [113]. Autophagy is another form of PCD,
hich suppresses tumorigenesis [114]. Thus, dysregulation of
utophagic pathways has recently been implicated in the patho-
enesis of a number of diseases including cancers [112,115].
t has been reported that GEN induced both apoptosis and
utophagy in several types of cancer cells including ovarian
ancer cells, human colon cancer HT-29 cells and lung cancer
ells [116–119]. It has been known that autophagy also plays an
mportant role in breast cancer [110–121]. It is likely that GEN
s able to stimulate autophagy in breast cancer cells and the pre-
ise roles of GEN in induction of autophagy in breast cancer
ells merit further investigations.
.  Summary  and  prospective
In this work, we reviewed the available information about
he consumption of soy foods, soy isoflavones and breast cancer
ncidence. First, we described briefly the history of soybean and
urrent status of soybean production as well as several types of
oy products and their nutritional functions and consumption.
here is an increasing trend in production and consumption of
oy foods in USA and around the world during the last decades.
everal lines of epidemiological evidence indicate a linear rela-
ionship between increasing soy consumption and a decreased
isk of recurrence and/or mortality of breast cancer, particularly
mong Chinese women. The possible molecular mechanisms
nvolved in the chemo-protective effects of GEN on breast cancer
nclude the effects of GEN as an agonist of ER, epigenetic and
enome-wide effects, activation of PPARs, induction of apopto-
is and stimulation of autophagy. However, the precise molecular
echanisms are still far from being clearly understood. Given
hat Chinese women have the tradition of consumption of more
oybean foods, which is related to lower breast cancer incidence
nd that there is an increasing trend of breast cancer incidence
n China, partially due to the recent switch of traditional dietary
tyles to the “Westernized” styles, it is important to conduct
 and H
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urther in depth and more comprehensive studies on the molec-
lar mechanisms underlying the protective effects of soybean
soflavones on breast cancer particularly in Chinese women.
hese studies would be valuable for paving a scientific basis
or future prevention and/or slowing down the increasing trend
f breast cancer in China by switching current “Westernized”
ietary styles back to the traditional dietary styles of consump-
ion of more soybean-derived foods.
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